Clinical Trials
10
Active:0
Completed:7
Trial Phases
3 Phases
Phase 1:2
Phase 2:3
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (44.4%)Phase 2
3 (33.3%)Phase 1
2 (22.2%)Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
- Conditions
- Peripheral Arterial Disease(PAD)Arterial Occlusive DiseaseArteriosclerosis ObliteransThromboangiitis ObliteransDiabetic Foot Ulcer (DFU)Diabetic Foot Ulcer IschemicCritical Limb Ischemia (CLI)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Target Recruit Count
- 542
- Registration Number
- NCT07023965
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chifeng Municipal Hospital, Chifeng, Neimenggu, China
🇨🇳zhongshan Hospital Affiliated of Dalian University, Dalian, Shenyang, China
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
Phase 2
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- Drug: PlaceboDrug: NL005 High DoseDrug: NL005 Middle Dose
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05984134
- Locations
- 🇨🇳
Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China
Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05968118
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
Phase 2
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- Drug: Low DoseDrug: Middle DoseDrug: High DoseOther: Placebo
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT05485818
- Locations
- 🇨🇳
Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04555824
- Locations
- 🇨🇳
Beijing Shijitan Hospital, Beijing, China
- Prev
- 1
- 2
- Next
News
No news found